{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:18:04Z","timestamp":1772140684029,"version":"3.50.1"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,2,14]]},"abstract":"<jats:p> PURPOSE: Although advances have been made in the treatment of AIDS-related Kaposi\u2019s sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed. IM862 is a naturally occurring peptide with antiangiogenic properties and was thus studied in patients with AIDS-KS. <\/jats:p><jats:p> PATIENTS AND METHODS: IM862 was given as intranasal drops at a dose of 5 mg. Patients were randomized to two dosing schedules given in repeated cycles until disease progression or unacceptable toxicity: 5 days of therapy followed by 5 days off (n = 18) and every other day dosing (n = 26). <\/jats:p><jats:p> RESULTS: Forty-two male patients and two female patients with a median age of 38 years (range, 22 to 53 years) were accrued. Twenty-one patients (47%) had more than 50 mucocutaneous lesions, 14 (32%) had lymphedema, and none had visceral involvement. Thirty-three patients (75%) had received prior systemic chemotherapy. Twenty-four patients (55%) had CD4<jats:sup>+<\/jats:sup> lymphocyte count \u2264 200\/mm<jats:sup>3<\/jats:sup>. All but five patients were being treated with concurrent protease inhibitor(s), for a median of 10 months (range, 0 to 24 months). Major responses were documented in 36%, with five complete and 11 partial remissions, occurring after a median of 6 weeks (range, 3 to 26 weeks) and lasting a median of 33+ weeks (range, 12+ to 95+ weeks). Twenty-one patients had stable disease for periods of 7 to 72+ weeks. Adverse effects to IM862 were limited to mild and transient headache, fatigue, tingling, and nausea. No hematologic adverse effects attributed to treatment were reported. <\/jats:p><jats:p> CONCLUSION: IM862 given as intranasal drops is well tolerated and has antitumor activity in patients with AIDS-KS. A randomized double-blinded study to define the activity of IM862 in patients with AIDS-KS is in progress. <\/jats:p>","DOI":"10.1200\/jco.2000.18.4.716","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:02:08Z","timestamp":1487919728000},"page":"716-716","source":"Crossref","is-referenced-by-count":61,"title":["Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-Related Kaposi\u2019s Sarcoma"],"prefix":"10.1200","volume":"18","author":[{"given":"Anil","family":"Tulpule","sequence":"first","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Scadden","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron M.","family":"Espina","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Cabriales","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Howard","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Shea","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parkash S.","family":"Gill","sequence":"additional","affiliation":[{"name":"From the Department of MedicineDivision of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA; and Department of Medicine, Division of Hematology, Massachusetts General Hospital, Harvard Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R2-0123","unstructured":"Gill  PS,  Hamilton  AW,  Naidu  Y:  Epidemic (AIDS-related) Kaposi\u2019s sarcoma:  Epidemiology, pathogenesis, and treatment. AIDS Updates 7:1,1994-11,"},{"key":"R3-0123","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199102000-00006"},{"key":"R4-0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.10.1115"},{"key":"R5-0123","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80081-V"},{"key":"R6-0123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92654-2"},{"key":"R7-0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"R8-0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.683"},{"key":"R9-0123","doi-asserted-by":"crossref","unstructured":"Tulpule  A,  Espina  BM,  Cabriales  S, et al:  IM-862 nasal solution is an active antiangiogenic agent in the treatment of AIDS-related Kaposi\u2019s sarcoma.  Proc Am Soc Clin Oncol 18:535a,1999  (abstr 2065)","DOI":"10.1200\/JCO.2000.18.4.716"},{"key":"R11-0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"R12-0123","doi-asserted-by":"publisher","DOI":"10.1007\/BF00944177"},{"key":"R13-0123","doi-asserted-by":"crossref","unstructured":"Mehta  CR,  Patel  NR:  A network algorithm for performing Fisher\u2019s exact test in r \u00d7 c contingency tables.  J Am Stat Assoc 78:427,1983-434,","DOI":"10.1080\/01621459.1983.10477989"},{"key":"R15-0123","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.13.974"},{"key":"R16-0123","doi-asserted-by":"crossref","unstructured":"Louie  S,  Cai  J,  Law  R, et al:  The effect of interleukin-1 and interleukin-1 antagonist in AIDS-Kaposi\u2019s sarcoma.  J Acquir Immune Defic Syndr Hum Retrovirol 4:455,1995-460,","DOI":"10.1097\/00042560-199504120-00004"},{"key":"R17-0123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4068"},{"key":"R18-0123","doi-asserted-by":"publisher","DOI":"10.1126\/science.1542792"},{"key":"R19-0123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1992.tb01412.x"},{"key":"R20-0123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.979"},{"key":"R21-0123","unstructured":"Mihalcea  AM,  Smith  DL,  Monini  P, et al:  Treatment update for AIDS-related Kaposi\u2019s sarcoma.  AIDS 13:S215,1999-S225,   (suppl A)"},{"key":"R22-0123","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.19.1585"},{"key":"R23-0123","doi-asserted-by":"publisher","DOI":"10.1177\/030089169608200412"},{"key":"R24-0123","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010638"},{"key":"R25-0123","unstructured":"Tulpule  A,  Snyder  JC,  Espina  BM, et al:  A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi\u2019s sarcoma and solid tumors.  Blood 84:248a,1994  (suppl 1)  (abstr)"},{"key":"R26-0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1444"},{"key":"R27-0123","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199711000-00015"},{"key":"R28-0123","doi-asserted-by":"crossref","unstructured":"Rabkin  CS,  Testa  MA,  Fischl  MA, et al:  Declining incidence of Kaposi\u2019s sarcoma in AIDS Clinical Trials Group (ACTG) Trials.  J Acquir Immune Defic Syndr Hum Retrovirol 17:A39,1988  (abstr)","DOI":"10.1097\/00042560-199804010-00125"},{"key":"R29-0123","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199710001-00007"},{"key":"R30-0123","unstructured":"Murphy  M,  Armstrong  D,  Sepkowitz  KA, et al:  Regression of AIDS-related Kaposi\u2019s sarcoma following treatment with an HIV-1 protease inhibitor.  AIDS 11:261,1997-262,"},{"key":"R31-0123","doi-asserted-by":"crossref","unstructured":"Bernstein  ZP,  Cohen  P,  Rios  A, et al:  A multicenter phase II\/III study of atragen (tretinoin liposomal) in patients with AIDS-associated Kaposi\u2019s sarcoma.  J Acquir Immune Defic Syndr Hum Retrovirol 14:A19,1997  (abstr)","DOI":"10.1097\/00042560-199704010-00055"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.4.716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:37:27Z","timestamp":1653514647000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.4.716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,14]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,2,14]]}},"alternative-id":["10.1200\/JCO.2000.18.4.716"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.4.716","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,14]]}}}